This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Shanxi Zhendong Pilot Biological Science and Technology Co., Ltd.. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Innovations of Huizi Jin in Myocarditis and Multiple Sclerosis Treatment
Introduction
Huizi Jin is a notable inventor based in Shanghai, China, recognized for his contributions to the field of biomedical science. He holds two patents that focus on innovative treatments for myocarditis and multiple sclerosis. His work demonstrates a commitment to advancing therapeutic options for serious health conditions.
Latest Patents
Huizi Jin's latest patents include "Line leaf inula flower lactone A and methods for preparing and using the same for treating myocarditis" and "Preparation and application of line leafflower lactone A for treating multiple sclerosis." The compound line leafflower lactone A has shown positive therapeutic activity against the Coxsackie virus and has a significant dose-dependent correlation. In mouse models of experimental autoimmune myocarditis, the compound prevents disease onset when administered intraperitoneally at a dose of 20 mg/kg/d. Increasing the dosage to 100 mg/kg/d enhances its therapeutic effects on experimental autoimmune myocarditis. The line leafflower lactone A is utilized as the sole active ingredient in various pharmaceutical forms, including tablets, capsules, and injections, for treating myocarditis. Additionally, it has therapeutic effects on experimental autoimmune encephalomyelitis, making it a promising candidate for developing drugs for multiple sclerosis.
Career Highlights
Huizi Jin is affiliated with Shanxi Zhendong Pilot Biological Science and Technology Co., Ltd., where he continues to innovate in the field of pharmaceutical sciences. His research has significant implications for the treatment of autoimmune diseases, showcasing his expertise and dedication to improving patient outcomes.
Collaborations
Some of Huizi Jin's notable coworkers include Weidong Zhang and Lei Shan, who contribute to the collaborative efforts in research and development within their organization.
Conclusion
Huizi Jin's innovative work in developing treatments for myocarditis and multiple sclerosis highlights his significant contributions to medical science. His patents reflect a promising future for therapeutic advancements in these critical areas.